A detailed history of Macquarie Group LTD transactions in Dexcom Inc stock. As of the latest transaction made, Macquarie Group LTD holds 1,536,292 shares of DXCM stock, worth $117 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
1,536,292
Previous 2,038,971 24.65%
Holding current value
$117 Million
Previous $231 Million 55.46%
% of portfolio
0.11%
Previous 0.27%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$64.0 - $116.06 $32.2 Million - $58.3 Million
-502,679 Reduced 24.65%
1,536,292 $103 Million
Q2 2024

Aug 09, 2024

SELL
$110.31 - $140.45 $19.6 Million - $25 Million
-177,711 Reduced 8.02%
2,038,971 $231 Million
Q1 2024

May 14, 2024

SELL
$114.22 - $140.1 $65.8 Million - $80.7 Million
-576,189 Reduced 20.63%
2,216,682 $307 Million
Q4 2023

Feb 14, 2024

SELL
$75.49 - $124.16 $18.2 Million - $29.9 Million
-240,608 Reduced 7.93%
2,792,871 $347 Million
Q3 2023

Nov 14, 2023

SELL
$86.06 - $137.93 $7.27 Million - $11.7 Million
-84,531 Reduced 2.71%
3,033,479 $283 Million
Q2 2023

Aug 14, 2023

SELL
$112.47 - $130.98 $20.5 Million - $23.8 Million
-181,857 Reduced 5.51%
3,118,010 $401 Million
Q1 2023

May 15, 2023

SELL
$104.0 - $122.92 $17 Million - $20.1 Million
-163,524 Reduced 4.72%
3,299,867 $383 Million
Q4 2022

Feb 21, 2023

SELL
$84.98 - $122.67 $16.3 Million - $23.6 Million
-192,010 Reduced 5.25%
3,463,391 $392 Million
Q3 2022

Nov 14, 2022

BUY
$76.35 - $94.18 $28.5 Million - $35.2 Million
373,898 Added 11.39%
3,655,401 $294 Million
Q2 2022

Aug 15, 2022

BUY
$67.99 - $132.89 $149 Million - $292 Million
2,195,727 Added 202.23%
3,281,503 $245 Million
Q1 2022

May 16, 2022

SELL
$94.08 - $130.2 $3.74 Million - $5.18 Million
-39,753 Reduced 3.53%
1,085,776 $555 Million
Q4 2021

Feb 11, 2022

BUY
$129.87 - $162.82 $31 Million - $38.8 Million
238,539 Added 26.89%
1,125,529 $604 Million
Q3 2021

Nov 12, 2021

SELL
$106.71 - $143.18 $6.72 Million - $9.02 Million
-63,001 Reduced 6.63%
886,990 $485 Million
Q2 2021

Aug 13, 2021

BUY
$80.99 - $107.93 $73 Million - $97.3 Million
901,709 Added 1867.59%
949,991 $406 Million
Q1 2021

May 14, 2021

SELL
$84.79 - $104.74 $131,848 - $162,870
-1,555 Reduced 3.12%
48,282 $17.4 Million
Q4 2020

Feb 16, 2021

BUY
$78.0 - $104.5 $485,550 - $650,512
6,225 Added 14.27%
49,837 $18.4 Million
Q3 2020

Nov 13, 2020

SELL
$95.51 - $112.95 $199,997 - $236,517
-2,094 Reduced 4.58%
43,612 $18 Million
Q2 2020

Aug 11, 2020

SELL
$62.68 - $105.34 $6.89 Million - $11.6 Million
-109,965 Reduced 70.64%
45,706 $18.5 Million
Q1 2020

May 15, 2020

BUY
$47.79 - $75.63 $1.32 Million - $2.09 Million
27,574 Added 21.53%
155,671 $41.9 Million
Q4 2019

Feb 14, 2020

SELL
$36.62 - $57.29 $1.96 Million - $3.07 Million
-53,577 Reduced 29.49%
128,097 $28 Million
Q3 2019

Nov 14, 2019

SELL
$35.53 - $43.8 $133,948 - $165,126
-3,770 Reduced 2.03%
181,674 $27.1 Million
Q2 2019

Aug 14, 2019

BUY
$27.84 - $38.92 $295,577 - $413,213
10,617 Added 6.07%
185,444 $27.8 Million
Q1 2019

May 15, 2019

SELL
$28.07 - $38.18 $239,886 - $326,286
-8,546 Reduced 4.66%
174,827 $20.8 Million
Q4 2018

Feb 15, 2019

SELL
$26.99 - $37.37 $347,496 - $481,138
-12,875 Reduced 6.56%
183,373 $22 Million
Q3 2018

Nov 15, 2018

SELL
$23.35 - $36.72 $936,171 - $1.47 Million
-40,093 Reduced 16.96%
196,248 $28.1 Million
Q2 2018

Aug 14, 2018

BUY
$17.54 - $25.22 $523,130 - $752,186
29,825 Added 14.44%
236,341 $22.4 Million
Q1 2018

May 11, 2018

BUY
$13.06 - $18.54 $239,507 - $340,005
18,339 Added 9.75%
206,516 $15.3 Million
Q4 2017

Feb 15, 2018

SELL
$11.12 - $15.38 $456,520 - $631,410
-41,054 Reduced 17.91%
188,177 $10.8 Million
Q3 2017

Nov 08, 2017

BUY
$11.36 - $18.98 $2.6 Million - $4.35 Million
229,231
229,231 $11.2 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $29.5B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.